RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2

(RTTNews) - Shares of RAPT Therapeutics Inc. (RAPT) have gained nearly 29 percent over the last five trading days as the Company gears up for some near-term clinical milestones.

RAPT is a clinical-stage immunology-based biopharmaceutical company focusing on oncology and inflammatory diseases.

The Company has two lead oral compounds, FLX475 for oncology and RPT193 for allergic inflammatory disease.

FLX475 is under a phase I/II trial as a monotherapy and in combination with Merck's (MRK) Keytruda in patients with "charged" tumors", including virally-associated cancers, gastric cancer, non-small cell lung cancer, triple-negative breast cancer, and head and neck cancers.

There was encouraging clinical activity in phase I portion of the FLX475 study. The results from the phase II portion of the trial are expected in the second quarter of 2020.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »